| Title | Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. |
| Publication Type | Journal Article |
| Year of Publication | 2016 |
| Authors | Shelef, A, Barak, Y, Berger, U, Paleacu, D, Tadger, S, Plopsky, I, Baruch, Y |
| Journal | J Alzheimers Dis |
| Volume | 51 |
| Issue | 1 |
| Pagination | 15-9 |
| Date Published | 2016 |
| ISSN | 1875-8908 |
| Keywords | Aged, Aged, 80 and over, Antipsychotic Agents, Behavioral Symptoms, Cognition Disorders, Dementia, Female, Humans, Male, Medical Marijuana, Neuropsychological Tests, Outcome Assessment (Health Care), Physical Examination, Pilot Projects, Prospective Studies, Psychiatric Status Rating Scales |
| Abstract | BACKGROUND: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD). OBJECTIVE: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD). METHODS: Eleven AD patients were recruited to an open label, 4 weeks, prospective trial. RESULTS: Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p CONCLUSION: Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option. |
| DOI | 10.3233/JAD-150915 |
| Alternate Journal | J. Alzheimers Dis. |
| PubMed ID | 26757043 |
